Real-World Comparative Effectiveness of Sacubitril/Valsartan Versus RAS Inhibition Alone in Patients with De Novo Heart Failure

Figures

• 

  Figure 1. Study design. Look‐back period: 2 years + 29 days up to, but not including, the index date. HF diagnosis date: earliest HF diagnosis within ≤30 days of index date. Index date: first prescription of sacubitril/valsartan or first/new prescription of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker in the identification period. Follow‐up period: from the day after the index date to the discontinuation day of the index medication, the end of activity in the database or the end of the study period. Identification period: 1 January 2016–31 March 2020.

• 

  Figure 2. Heart failure medication use at baseline in propensity score‐matched sacubitril/valsartan and angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) cohorts. MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium–glucose cotransporter 2 inhibitor.

• 

  Figure 3. Kaplan–Meier plots of freedom from all‐cause hospitalization in propensity score‐matched sacubitril/valsartan and angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) cohorts during the entire follow‐up period. CI, confidence interval; IRR, incidence rate ratio.

• 

  Figure 4. All‐cause hospitalization in propensity score‐matched sacubitril/valsartan and angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) cohorts across subgroups during the entire follow‐up period. AF, atrial fibrillation; CI, confidence interval; CKD, chronic kidney disease; IRR, incidence rate ratio; MI, myocardial infarction; PY, patient years; y, years.

• 

  Figure 5. Key secondary endpoints in propensity score‐matched sacubitril/valsartan versus angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) cohorts during the entire follow‐up period: (A) cardiovascular (CV) hospitalization and (B) heart failure (HF) hospitalization. CI, confidence interval; IRR, incidence rate ratio.

• 

  Figure 6. Total mortality in propensity score‐matched sacubitril/valsartan versus angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) cohorts. CI, confidence interval; IRR, incidence rate ratio.